Blood Cancer Journal - Table of Contents alert Volume 6 January 2016

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 6, January 2016 In this issue Commentary Original Articles Letters to the Editor Sign up for e-alerts Web feed Advertisement Blood Cancer Journal is an online-only, open access journal, publishing high quality research on hematologic malignancies and related disorders.The journal has an Impact Factor of 3.467. Explore the benefits of submitting your next research article. Commentary Top PPARγ ligands increase antileukemic activity of second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia cells E Glodkowska-Mrowka, A Manda-Handzlik, A Stelmaszczyk-Emmel, I Seferynska, T Stoklosa, J Przybylski and P Mrowka Blood Cancer J 2016 6: e377; 10.1038/bcj.2015.109 Full Text Original Articles Top Infectious complications in children with acute myeloid leukemia: decreased mortality in multicenter trial AML-BFM 2004 K Bochennek, A Hassler, C Perner, J Gilfert, S Schöning, T Klingebiel, D Reinhardt, U Creutzig and T Lehrnbecher Blood Cancer J 2016 6: e382; 10.1038/bcj.2015.110 Abstract | Full Text RUNX1 haploinsufficiency results in granulocyte colony-stimulating factor hypersensitivity D W L Chin, M Sakurai, G S S Nah, L Du, B Jacob, T Yokomizo, T Matsumura, T Suda, G Huang, X-Y Fu, Y Ito, H Nakajima and M Osato Blood Cancer J 2016 6: e379; 10.1038/bcj.2015.105 Abstract | Full Text miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth M Fulciniti, N Amodio, R L Bandi, A Cagnetta, M K Samur, C Acharya, R Prabhala, P D'Aquila, D Bellizzi, G Passarino, S Adamia, A Neri, Z R Hunter, S P Treon, K C Anderson, P Tassone and N C Munshi Blood Cancer J 2016 6: e380; 10.1038/bcj.2015.106 Abstract | Full Text Significance of KIT exon 17 mutation depends on mutant level rather than positivity in core-binding factor acute myeloid leukemia W Jang, J-H Yoon, J Park, G D Lee, J Kim, A Kwon, H Choi, K Han, C H Nahm, H-J Kim, W-S Min, M Kim and Y Kim Blood Cancer J 2016 6: e387; 10.1038/bcj.2015.116 Abstract | Full Text Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia M M Patnaik, T L Lasho, P Vijayvargiya, C M Finke, C A Hanson, R P Ketterling, N Gangat and A Tefferi Blood Cancer J 2016 6: e385; 10.1038/bcj.2015.113 Abstract | Full Text Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial N Raje, S Vadhan-Raj, W Willenbacher, E Terpos, V Hungria, A Spencer, Y Alexeeva, T Facon, A K Stewart, A Feng, A Braun, A Balakumaran and G D Roodman Blood Cancer J 2016 6: e378; 10.1038/bcj.2015.96 Abstract | Full Text Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? A Rosenthal, J Luthi, M Belohlavek, K M Kortüm, F Mookadam, A Mayo, R Fonseca, P L Bergsagel, C B Reeder, J R Mikhael and A K Stewart Blood Cancer J 2016 6: e384; 10.1038/bcj.2015.112 Abstract | Full Text Karyotype complexity and prognosis in acute myeloid leukemia F Stölzel, B Mohr, M Kramer, U Oelschlägel, T Bochtler, W E Berdel, M Kaufmann, C D Baldus, K Schäfer-Eckart, R Stuhlmann, H Einsele, S W Krause, H Serve, M Hänel, R Herbst, A Neubauer, K Sohlbach, J Mayer, J M Middeke, U Platzbecker, M Schaich, A Krämer, C Röllig, J Schetelig, M Bornhäuser and G Ehninger Blood Cancer J 2016 6: e386; 10.1038/bcj.2015.114 Abstract | Full Text Letters to the Editor Top Nurse-like cells impact on disease progression in chronic lymphocytic leukemia F Boissard, C Laurent, A G Ramsay, A Quillet-Mary, J-J Fournié, M Poupot and L Ysebaert Blood Cancer J 2016 6: e381; 10.1038/bcj.2015.108 Full Text Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups A-L Gagez, E Tuaillon, R Cezar, C Dartigeas, B Mahé, R Letestu, H Maisonneuve, V Gouilleux-Gruart, K Bollore, E Ferrant, T Aurran, P Feugier, S Leprêtre and G Cartron Blood Cancer J 2016 6: e389; 10.1038/bcj.2015.115 Full Text The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era T Kobayashi, J Kuroda, I Yokota, K Tanba, T Fujino, S Kuwahara, R Isa, J Yamaguchi, E Kawata, T Akaogi, H Uchiyama, H Kaneko, N Uoshima, Y Kobayashi, S Teramukai and M Taniwaki Blood Cancer J 2016 6: e383; 10.1038/bcj.2015.111 Full Text High expression of PTPN21 in B-cell non-Hodgkin’s gastric lymphoma, a positive mediator of STAT5 activity J H C Plani-Lam, T C Chow, Y-H Fan, B Garcia-Bloj, L Cheng, D Y Jin, W Hancock, S Fanayan, E Ingley and Y-Q Song Blood Cancer J 2016 6: e388; 10.1038/bcj.2015.107 Full Text You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.